Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 90

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 90
---
 domestic issuers. Such conversion and modifications will involve additional costs.
In addition, we would lose our ability to rely upon exemptions from certain corporate governance requirements on U. S. stock exchanges
that are available to foreign private issuers.

We are an emerging growth company and the reduced disclosure requirements
applicable to emerging growth companies may make our Common Shares less attractive to investors.

We are an emerging growth company, as defined in
the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other public companies
that are not emerging growth companies.

For as long as we remain an emerging growth company
we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that
are not “emerging growth companies.” These exemptions include:

  not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;                                                            
  Section 107 of the JOBS Act, which provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, ...  
  not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s r...  
  reduced disclosure obligations regarding executive compensation; and                                                                                                                                  
  exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.                   

We will remain an emerging growth company until
the earliest of: (i) the last day of our fiscal year during which we have total annual gross revenues of at least $1.235 billion; (ii)
October 31, 2025; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible
debt; or (iv) the date on which we are deemed to be a “large accelerated filer” under the Exchange Act. We have opted out
of the extended transition period made available to emerging growth companies to comply with newly adopted public company accounting requirements.

When we are no longer deemed to be an emerging
growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We cannot predict if investors will
find our Common Shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find our Common